相似文献
1
Changing paradigms in the treatment of multiple myeloma.
Haematologica. 2009 Feb;94(2):163-6. doi: 10.3324/haematol.2008.002766.
2
Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma.
Bone Marrow Transplant. 2018 Apr;53(4):507-510. doi: 10.1038/s41409-017-0069-1. Epub 2018 Jan 12.
3
The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant.
Bone Marrow Transplant. 2018 Nov;53(11):1483-1486. doi: 10.1038/s41409-018-0216-3. Epub 2018 May 24.
4
Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
Bone Marrow Transplant. 2003 Aug;32(3):343. doi: 10.1038/sj.bmt.1704140.
5
Salvage second transplantation in relapsed multiple myeloma.
Leukemia. 2021 Apr;35(4):1214-1217. doi: 10.1038/s41375-020-1005-8. Epub 2020 Aug 4.
6
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Bone Marrow Transplant. 2003 Jun;31(11):1065; author reply 1067. doi: 10.1038/sj.bmt.1704079.
7
Pretransplant induction regimens for multiple myeloma.
Biol Blood Marrow Transplant. 2015 Feb;21(2):200-1. doi: 10.1016/j.bbmt.2014.12.013. Epub 2014 Dec 19.
8
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9.
9
Multiple myeloma.
Hematol Oncol Clin North Am. 2014 Dec;28(6):1113-29. doi: 10.1016/j.hoc.2014.08.010. Epub 2014 Sep 30.
10
Tandem bone marrow transplantation in multiple myeloma.
N Engl J Med. 2004 Apr 1;350(14):1466-7; author reply 1466-7.
引用本文的文献
1
Characterization and prognostic features of secondary acute myeloid leukemia in survivors of multiple myeloma.
Am J Cancer Res. 2023 Oct 15;13(10):4803-4810. eCollection 2023.
2
Clinical outcomes and complications of surgical interventions for multiple myeloma lesions in the extremities and pelvis: A retrospective clinical study.
Acta Orthop Traumatol Turc. 2021 Mar;55(2):159-165. doi: 10.5152/j.aott.2021.20130.
3
Strategies to improve patient-reported outcome completion rates in longitudinal studies.
Qual Life Res. 2020 Feb;29(2):335-346. doi: 10.1007/s11136-019-02304-8. Epub 2019 Sep 23.
4
Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
Radiat Oncol J. 2016 Mar;34(1):59-63. doi: 10.3857/roj.2016.34.1.59. Epub 2016 Mar 30.
5
Current role of radiation therapy for multiple myeloma.
Front Oncol. 2015 Feb 18;5:40. doi: 10.3389/fonc.2015.00040. eCollection 2015.
6
Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.
Adv Ther. 2014 Oct;31(10):1082-94. doi: 10.1007/s12325-014-0159-z. Epub 2014 Oct 21.
7
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
PLoS One. 2014 Jan 27;9(1):e85059. doi: 10.1371/journal.pone.0085059. eCollection 2014.
8
Oral status of patients submitted to autologous hematopoietic stem cell transplantation.
Support Care Cancer. 2014 Jan;22(1):15-21. doi: 10.1007/s00520-013-1940-2. Epub 2013 Aug 24.
9
Novel drugs for the treatment of multiple myeloma.
Haematologica. 2010 May;95(5):702-4. doi: 10.3324/haematol.2009.021550.
本文引用的文献
1
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.
Haematologica. 2009 Feb;94(2):270-5. doi: 10.3324/haematol.13782. Epub 2009 Jan 14.
2
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Blood. 2009 Apr 9;113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.
3
Advances in therapy of multiple myeloma.
Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984.
4
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.
5
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Blood. 2008 Nov 1;112(9):3591-3. doi: 10.1182/blood-2008-02-141598. Epub 2008 Jul 8.
6
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
J Clin Oncol. 2008 May 1;26(13):2171-7. doi: 10.1200/JCO.2007.14.1853. Epub 2008 Mar 24.
7
Thalidomide for treatment of multiple myeloma: 10 years later.
Blood. 2008 Apr 15;111(8):3968-77. doi: 10.1182/blood-2007-10-117457. Epub 2008 Feb 1.
8
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
9
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
N Engl J Med. 2007 Nov 22;357(21):2123-32. doi: 10.1056/NEJMoa070594.
10
Role of stem cell transplantation.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1157-74, x. doi: 10.1016/j.hoc.2007.08.001.
Zotero 插件